|
[1] YOUNOSSI ZM. Non-alcoholic fatty liver disease-A global public health perspective[J]. J Hepatol,2019,70(3):531-544.
|
|
[2] CAO MB,DONG L,LU XL,et al. Expression of cyclooxygenase-2 in nonalcoholic fatty liver disease and its significance[J]. J Fourth Milit Med Univ,2008,29(14):1282-1285.(in Chinese)曹名波，董蕾，鲁晓岚，等．环氧合酶-2在非酒精性脂肪肝病中的表达及意义[J]．第四军医大学学报，2008,29(14):1282-1285.
|
|
[3] CUSI K. Role of insulin resistance and lipotoxicity in non-alcoholic steatohepatitis[J]. Clin Liver Dis,2009,13(4):545-563.
|
|
[4] FOURET G,GAILLET S,LECOMTE J,et al. 20-Week fol owup of hepatic steatosis installation and liver mitochondrial structure and activity and their interrelation in rats fed a high-fat-highfructose diet[J]. Br J Nutr,2018,119(4):368-380.
|
|
[5] LIU Z,HUANG Y,ZHANG Y,et al. Drosophila Acyl-Co A synthetase long-chain family member 4 regulates axonal transport of synaptic vesicles and is required for synaptic development and transmission[J]. Neurosci,2011,31(6):2052-2063.
|
|
[6] KRAWCZYK M,BONFRATE L,PORTINCASA P,et al. Nonalcoholic fatty liver disease[J]. Best Pract Res Clin Gastroenterol,2010,24(5):695-708.
|
|
[7] VELAGAPUDI VR,HEZAVEH R,REIGSTAD CS,et al. The gut microbiota modulates host energy and lipid metabolism in mice[J]. J Lipid Res,2010,51(5):1101-1112.
|
|
[8] JING XY,YANG XF. The effect of COX-2 on expression of Acsl family related genes in HSC-T6 cells[D]. Hengyang:The University of South China,2014.(in Chinese)靖新艳，阳学风．COX-2对HSC-T6细胞中Acsl家族相关基因表达的影响[D]．衡阳:南华大学，2014.
|
|
[9] BAFFY G. Potential mechanisms linking gut microbiota and portal hypertension[J]. Liver Int,2019,39(4):598-609.
|
|
[10] LAU E,CARVALHO D,FREITAS P. Gut microbiota:Association with NAFLD and metabolic disturbances[J]. Biomed Res Int,2015,2015:979515.
|
|
[11] SUO YH,LIU JC. Research advances in the treatment of nonalcoholic fatty liver disease[J]. J Clin Hepatol,2018,34(10):2232-2236.(in Chinese)索宇鸿，刘近春．非酒精性脂肪性肝病的治疗进展[J]．临床肝胆病杂志，2018,34(10):2232-2236.
|
|
[12] COHEN JC,HORTON JD,HOBBS HH. Human fatty liver disease:Old questions and new insights[J]. Science,2011,332(6037):1519-1523.
|
|
[13] ISMAIL SA,SH ES,ZIADA DH,et al. Cytokeratin-18 in diagnosis of HCC in patients with liver cirrhosis[J]. Asian Pac J Cancer Prev,2017,18(4):1105-1111.
|
|
[14] BYRNE CD,TARGHER G. NAFLD:A multisystem disease[J]. J Hepatol,2015,62(1 Suppl):s47-s64.
|
|
[15] LI WY,YUAN CM. Research advances in integrated traditional Chinese and Western medicine therapy for nonalcoholic fatty liver disease[J]. J Clin Hepatol,2020,36(4):919-923.(in Chinese)李文怡，袁成民．非酒精性脂肪性肝病的中西医治疗[J]．临床肝胆病杂志，2020,36(4):919-923.
|
|
[16] TAKAKI A,KAWAI D,YAMAMOTO K. Multiple hits,including oxidative stress,as pathogenesis and treatment target in non-alcoholic steatohepatitis(NASH)[J]. Int J Mol Sci,2013,14(10):20704-20728.
|
|
[17] JASIRWAN C,LESMANA C,HASAN I,et al. The role of gut microbiota in non-alcoholic fatty liver disease:Pathways of mechanisms[J]. Biosci Microbiota Food Health,2019,38(3):81-88.
|
|
[18] VEENA J,MURAGUNDLA A,SIDGIDDI S,et al. Non-alcoholic fatty liver disease:Need for a balanced nutritional source[J]. Br J Nutr,2014,112(11):1858-1872.
|
|
[19] MOURIES J,BRESCIA P,SILVESTRI A,et al. Microbiotadriven gut vascular barrier disruption is a prerequisite for nonalcoholic steatohepatitis development[J]. J Hepatol,2019,71(6):1216-1228.
|
|
[20] SCHNEIDER KM,BIEGHS V,HEYMANN F,et al. CX3CR1 is a gatekeeper for intestinal barrier integrity in mice:Limiting steatohepatitis by maintaining intestinal homeostasis[J]. Hepatology,2015,62(5):1405-1416.
|
|
[21] PETITO-DA-SILVA TI,SOUZA-MELLO V,BARBOSA-DASILVA S. Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance,lipogenesis and ER stress[J]. Mol Cel Endocrinol,2019,498:110539.
|
|
[22] HU J,HONG W,YAO KN,et al. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/m TOR/SREBP-1 signaling pathway[J]. World J Gastroenterol,2019,25(12):1492-1501.
|
|
[23] ZHANG C,Mc FARLANE C,LOKIREDDY S,et al. Inhibition of myostatin protects against diet-induced obesityby enhancing fatty acid oxidation and promoting a brown adipose phenotype in mice[J]. Diabetologia,2012,55(1):183-193.
|
|
[24] TAI FWD. NSAIDs and the small bowel[J]. Current opinion in gastroenterology,2018,12(2):431-455.
|
|
[25] TTHˇS,JONECOVZ,C`URGALI K,et al. Quercetin attenuates the ischemia reperfusion induced COX-2 and MPO expression in the small intestine mucosa[J]. Biomed Pharmacother,2017,95:346-354.
|
|
[26] NEESS D,BEK S,ENGELSBY H,et al. Long-chain acylCo A esters in metabolism and signaling:Role of acyl-Co A binding proteins[J]. Prog Lipid Res,2015,59:1-25.
|
|
[27] POPPELREUTHER M,RUDOLPH B,DU C,et al. The N-terminal region of acyl-Co A synthetase 3 is essential for both the localization on lipid droplets and the function in fatty acid uptake[J]. J Lipid Res,2012,53(5):888-900.
|
|
[28] BAUER PV,DUCA FA,WAISE T,et al. Lactobacillus gasseri in the upper small intestine impacts an ACSL3-dependent fatty acid-sensing pathway regulating whole-body glucose homeostasis[J]. Cell Metab,2018,27(3):572-587. e6.
|
|
[29] REINARTZ A,EHLING J,LEUE A,et al. Lipid-induced upregulation of human acyl-Co A synthetase 5 promotes hepatocellular apoptosis[J]. Biochim Biophys Acta,2010,1801(9):1025-1035.
|
|
[30] TSUJIMOTO S,KISHINA M,KODA M,et al. Nimesulide,a cyclooxygenase-2 selective inhibitor,suppresses obesityrelated non-alcoholic fatty liver disease and hepatic insulin resistance through the regulation of peroxisome proliferator-activated receptorγ[J]. Int J Mol Med,2016,38(3):721-728.
|
DownLoad: